The New York Times, August 4, 2020


Novavax, the little-known Maryland company that received a $1.6 billion deal from the federal government for its experimental coronavirus vaccine, announced encouraging results in two preliminary studies on Tuesday.

In one study, 56 volunteers produced a high level of antibodies against the virus without any dangerous side effects. In the other, researchers found that the vaccine strongly protected monkeys from coronavirus infections.

Although it’s not possible to directly compare the data from clinical trials of different coronavirus vaccines, John Moore, a virologist at Weill Cornell Medicine who was not involved in the studies, said the Novavax results were the most impressive he had seen so far.

Continue reading “Scientists Are Optimistic About New Vaccine Studies From Novavax”

The New York Times, July 30, 2020


An experimental coronavirus vaccine developed by Johnson & Johnson protected monkeys from infection in a new study. It is the second vaccine candidate to show promising results in monkeys this week.

The company recently began a clinical trial in Europe and the United States to test its vaccine in people. It is one of more than 30 human trials for coronavirus vaccines underway across the world. But until these trials are complete — which will probably take several months — the monkey data offers the best clues to whether the vaccines will work.

Continue reading “Johnson & Johnson’s Coronavirus Vaccine Protects Monkeys, Study Finds”

The New York Times, July 17, 2020


Each workday morning in March, Noe Mercado drove through the desolate streets of Boston to a tall glass building on Blackfan Circle, in the heart of the city’s biotech hub. Most residents had gone into hiding from the coronavirus, but Mr. Mercado had an essential job: searching for a vaccine against this new, devastating pathogen.

Parking in the underground lot, he put on a mask and rode the empty elevator to the tenth floor, joining a skeleton crew at the Center for Virology and Vaccine Research at Beth Israel Deaconess Medical Center. Day after day, Mr. Mercado sat at his lab bench, searching for signs of the virus in nasal swabs taken from dozens of monkeys.

Continue reading “Inside Johnson & Johnson’s Nonstop Hunt for a Coronavirus Vaccine”

The New York Times, July 15, 2020


The Covid-19 pandemic is one of the greatest challenges modern medicine has ever faced. Doctors and scientists are scrambling to find treatments and drugs that can save the lives of infected people and perhaps even prevent infection.

Below is an updated list of 19 of the most-talked-about treatments for the coronavirus. While some are accumulating evidence that they’re effective, most are still at early stages of research. We also included a warning about a few that are just bunk.

Continue reading “Coronavirus Drug and Treatment Tracker”

The New York Times, July 15, 2020


Early in the Covid-19 pandemic, researchers found preliminary evidence suggesting that people’s blood type might be an important risk factor — both for being infected by the virus and for falling dangerously ill.

But over the past few months, after looking at thousands of additional patients with Covid-19, scientists are reporting a much weaker link to blood type.

Two studies — one at the Massachusetts General Hospital and the other at Columbia Presbyterian Hospital in New York — did not find that Type A blood increases the odds that people will be infected with Covid-19.

Continue reading “Covid-19 Risk Doesn’t Depend (Much) on Blood Type, New Studies Find”